Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID‐19

Analysis of 2,433 events reported on the FDA Adverse Event Reporting System found increased reporting of hepatic (n = 91), pancreatic (151) and pulmonary fibrosis (222) reactions, which require consideration in patient care and monitoring of ongoing clinical trials.

Source:

British Journal of Clinical Pharmacology